Complix Funding: How Much Did They Raise & Key Investors

How Much Did Complix Raise?
Funding & Key Investors

Complix has successfully navigated multiple financing rounds to advance its proprietary biopharmaceutical platform, securing a total of $22.3M in capital to date. The company's most recent strategic investment of $600K underscores its commitment to overcoming traditional therapeutic limitations. By focusing on the development of Cell Penetrating Alphabody (CPAB) therapeutics, Complix has positioned itself as a critical player in the biotechnology sector, attracting significant backing from institutional investors and venture capital firms dedicated to life sciences innovation.

The firm's growth trajectory, marked by a series of capital injections, reflects a robust development pipeline aimed at addressing previously undruggable intracellular targets. This financial foundation provides the necessary runway to transition from early-stage research into more advanced clinical development phases, ensuring that their innovative delivery methods for cancer and autoimmune disorder treatments remain on a competitive path.

What is Complix?

Complix

Manufacturing

Pharmaceuticals

Business Services

Complix is a specialized biopharmaceutical enterprise focused on the engineering of Cell Penetrating Alphabodies (CPABs). These novel therapeutic agents are designed to penetrate cells and interact with intracellular targets that have historically been considered undruggable. By leveraging this proprietary technology, the company aims to revolutionize the treatment landscape for life-threatening conditions, including various forms of cancer and complex autoimmune diseases. Their market position is defined by a commitment to high-impact R&D and the exploration of non-injectable delivery mechanisms, which could significantly improve patient outcomes and therapeutic accessibility.

How much funding has Complix raised?

Complix has raised a total of $22.3M across 3 funding rounds:

2010

Series A

$6.2M

2013

Series B

$15.5M

2017

Grant

$600K

Series A (2010): $6.2M with participation from Lrm, Vesalius Biocapital Partners, and CRP Sante

Series B (2013): $15.5M led by Vesalius Biocapital Partners, Edmond de Rothschild Investment Partners, Gimv, OMNES Capital, CRP-Sante, Baekeland Fund, and TrustCapital

Grant (2017): $600K, investors not publicly disclosed

Key Investors in Complix

Vesalius Biocapital Partners

A venture capital firm specializing in European life science companies, focusing on human health through investments in therapeutics, medical devices, and diagnostics.

Edmond de Rothschild Investment Partners

A long-standing French investment banking institution providing comprehensive financial services and strategic capital solutions to high-growth enterprises.

Lrm

A venture capital provider focused on economic development and innovation, supporting startups and businesses through smart money and extensive regional networks.

What's next for Complix?

With the support of its recent strategic financing, Complix is poised to accelerate its pipeline development and expand its collaborative efforts. The company's strategic roadmap emphasizes the validation of its Alphabody platform through clinical milestones and the pursuit of high-value partnerships. As the firm continues to refine its therapeutic interventions, the focus will likely shift toward scaling manufacturing capabilities and optimizing the delivery of its lead candidates. By maintaining a disciplined approach to capital allocation, Complix aims to solidify its role as a leader in intracellular drug discovery, ultimately bridging the gap between complex biological research and viable, transformative patient care.

See full Complix company page

See More Financial Insights